Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrroles
  • Receptors, Platelet-Derived Growth Factor
  • Receptors, Vascular Endothelial Growth Factor

abstract

  • SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF and PDGF receptors, demonstrates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently recognized. The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC.

publication date

  • January 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.02.2574

PubMed ID

  • 16330672

Additional Document Info

start page

  • 16

end page

  • 24

volume

  • 24

number

  • 1